Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer.

Guo J, Yang WL, Pak D, Celestino J, Lu KH, Ning J, Lokshin AE, Cheng Z, Lu Z, Bast RC Jr.

Cancers (Basel). 2019 Apr 28;11(5). pii: E596. doi: 10.3390/cancers11050596.

2.

Melanoma-Induced Reprogramming of Schwann Cell Signaling Aids Tumor Growth.

Shurin GV, Kruglov O, Ding F, Lin Y, Hao X, Keskinov AA, You Z, Lokshin AE, LaFramboise WA, Falo LD Jr, Shurin MR, Bunimovich YL.

Cancer Res. 2019 May 15;79(10):2736-2747. doi: 10.1158/0008-5472.CAN-18-3872. Epub 2019 Mar 26.

PMID:
30914431
3.

Changes in inflammatory endometrial cancer risk biomarkers in individuals undergoing surgical weight loss.

Linkov F, Goughnour SL, Ma T, Xu Z, Edwards RP, Lokshin AE, Ramanathan RC, Hamad GG, McCloskey C, Bovbjerg DH.

Gynecol Oncol. 2017 Oct;147(1):133-138. doi: 10.1016/j.ygyno.2017.07.144. Epub 2017 Aug 7.

4.

Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Al Efishat MA, Attiyeh MA, Eaton AA, Gönen M, Prosser D, Lokshin AE, Castillo CF, Lillemoe KD, Ferrone CR, Pergolini I, Mino-Kenudson M, Rezaee N, Dal Molin M, Weiss MJ, Cameron JL, Hruban RH, D'Angelica MI, Kingham TP, DeMatteo RP, Jarnagin WR, Wolfgang CL, Allen PJ.

Ann Surg. 2018 Aug;268(2):340-347. doi: 10.1097/SLA.0000000000002421.

PMID:
28700444
5.

Quantification of autoantibodies to plasminogen in plasma of patients with cancer.

Goufman EI, Iakovlev VN, Tikhonova NB, Lokshin AE.

Cancer Biomark. 2015;15(3):281-7. doi: 10.3233/CBM-150469.

PMID:
25769452
6.

Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer.

Mirus JE, Zhang Y, Li CI, Lokshin AE, Prentice RL, Hingorani SR, Lampe PD.

Clin Cancer Res. 2015 Apr 1;21(7):1764-71. doi: 10.1158/1078-0432.CCR-13-3474. Epub 2015 Jan 14.

7.

Urinary protein biomarkers in the early detection of lung cancer.

Nolen BM, Lomakin A, Marrangoni A, Velikokhatnaya L, Prosser D, Lokshin AE.

Cancer Prev Res (Phila). 2015 Feb;8(2):111-9. doi: 10.1158/1940-6207.CAPR-14-0210. Epub 2014 Nov 21.

8.

Circulating mediators of inflammation and immune activation in AIDS-related non-hodgkin lymphoma.

Nolen BM, Breen EC, Bream JH, Jenkins FJ, Kingsley LA, Rinaldo CR, Lokshin AE.

PLoS One. 2014 Jun 12;9(6):e99144. doi: 10.1371/journal.pone.0099144. eCollection 2014.

9.

Distinct age-matched serum biomarker profiles in patients with cutaneous T-cell lymphoma.

Geskin LJ, Akilov OE, Lin Y, Lokshin AE.

Exp Dermatol. 2014 Aug;23(8):598-600. doi: 10.1111/exd.12455. Epub 2014 Jul 16.

10.

Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study.

Nolen BM, Brand RE, Prosser D, Velikokhatnaya L, Allen PJ, Zeh HJ, Grizzle WE, Huang Y, Lomakin A, Lokshin AE.

PLoS One. 2014 Apr 18;9(4):e94928. doi: 10.1371/journal.pone.0094928. eCollection 2014. Erratum in: PLoS One. 2015;10(2):e0117876. Huang, Ying [added].

11.

An extensive targeted proteomic analysis of disease-related protein biomarkers in urine from healthy donors.

Nolen BM, Orlichenko LS, Marrangoni A, Velikokhatnaya L, Prosser D, Grizzle WE, Ho K, Jenkins FJ, Bovbjerg DH, Lokshin AE.

PLoS One. 2013 May 28;8(5):e63368. doi: 10.1371/journal.pone.0063368. Print 2013.

12.

Biomarker testing for ovarian cancer: clinical utility of multiplex assays.

Nolen BM, Lokshin AE.

Mol Diagn Ther. 2013 Jun;17(3):139-46. doi: 10.1007/s40291-013-0027-6. Review.

13.

Circulating prolactin levels and risk of epithelial ovarian cancer.

Clendenen TV, Arslan AA, Lokshin AE, Liu M, Lundin E, Koenig KL, Berrino F, Hallmans G, Idahl A, Krogh V, Lukanova A, Marrangoni A, Muti P, Nolen BM, Ohlson N, Shore RE, Sieri S, Zeleniuch-Jacquotte A.

Cancer Causes Control. 2013 Apr;24(4):741-8. doi: 10.1007/s10552-013-0156-6. Epub 2013 Feb 3.

14.

The quest for ovarian cancer screening biomarkers: are we on the right road?

Lokshin AE.

Int J Gynecol Cancer. 2012 May;22 Suppl 1:S35-40. doi: 10.1097/IGC.0b013e318251ccaa.

PMID:
22543919
15.

Multianalyte assay systems in the differential diagnosis of ovarian cancer.

Nolen BM, Lokshin AE.

Expert Opin Med Diagn. 2012 Mar;6(2):131-138.

16.

A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening.

Bigbee WL, Gopalakrishnan V, Weissfeld JL, Wilson DO, Dacic S, Lokshin AE, Siegfried JM.

J Thorac Oncol. 2012 Apr;7(4):698-708. doi: 10.1097/JTO.0b013e31824ab6b0.

17.

Serum biomarker profiles as diagnostic tools in lung cancer.

Nolen BM, Langmead CJ, Choi S, Lomakin A, Marrangoni A, Bigbee WL, Weissfeld JL, Wilson DO, Dacic S, Siegfried JM, Lokshin AE.

Cancer Biomark. 2011-2012;10(1):3-12. doi: 10.3233/CBM-2012-0229.

18.

Protein biomarkers of ovarian cancer: the forest and the trees.

Nolen BM, Lokshin AE.

Future Oncol. 2012 Jan;8(1):55-71. doi: 10.2217/fon.11.135. Review.

19.

Factors associated with inflammation markers, a cross-sectional analysis.

Clendenen TV, Koenig KL, Arslan AA, Lukanova A, Berrino F, Gu Y, Hallmans G, Idahl A, Krogh V, Lokshin AE, Lundin E, Muti P, Marrangoni A, Nolen BM, Ohlson N, Shore RE, Sieri S, Zeleniuch-Jacquotte A.

Cytokine. 2011 Dec;56(3):769-78. doi: 10.1016/j.cyto.2011.09.013. Epub 2011 Oct 19.

20.

-The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid.

Nolen BM, Lokshin AE.

Int J Biol Markers. 2011 Jul-Sep;26(3):141-52. doi: 10.5301/JBM.2011.8613. Epub 2011 Sep 21. Review.

21.

Inflammatory signaling compromises cell responses to interferon alpha.

Huangfu WC, Qian J, Liu C, Liu J, Lokshin AE, Baker DP, Rui H, Fuchs SY.

Oncogene. 2012 Jan 12;31(2):161-72. doi: 10.1038/onc.2011.221. Epub 2011 Jun 13.

22.

Circulating inflammation markers and risk of epithelial ovarian cancer.

Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, Koenig KL, Berrino F, Lukanova A, Lokshin AE, Idahl A, Ohlson N, Hallmans G, Krogh V, Sieri S, Muti P, Marrangoni A, Nolen BM, Liu M, Shore RE, Arslan AA.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):799-810. doi: 10.1158/1055-9965.EPI-10-1180. Epub 2011 Apr 5.

23.

A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.

Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD; PLCO Project Team.

Cancer Prev Res (Phila). 2011 Mar;4(3):375-83. doi: 10.1158/1940-6207.CAPR-10-0193.

24.

Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.

Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N.

Cancer Prev Res (Phila). 2011 Mar;4(3):365-74. doi: 10.1158/1940-6207.CAPR-10-0195.

25.

Serum biomarker panels for the detection of pancreatic cancer.

Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD, Vickers SM, Langmead CJ, Landsittel DP, Whitcomb DC, Grizzle WE, Lokshin AE.

Clin Cancer Res. 2011 Feb 15;17(4):805-16. doi: 10.1158/1078-0432.CCR-10-0248.

26.

Temporal reliability of cytokines and growth factors in EDTA plasma.

Clendenen TV, Arslan AA, Lokshin AE, Idahl A, Hallmans G, Koenig KL, Marrangoni AM, Nolen BM, Ohlson N, Zeleniuch-Jacquotte A, Lundin E.

BMC Res Notes. 2010 Nov 13;3:302. doi: 10.1186/1756-0500-3-302.

27.

Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study.

Gu Y, Shore RE, Arslan AA, Koenig KL, Liu M, Ibrahim S, Lokshin AE, Zeleniuch-Jacquotte A.

Cancer Causes Control. 2010 Aug;21(8):1323-33. doi: 10.1007/s10552-010-9560-3. Epub 2010 Apr 7.

28.

Development of a multimarker assay for early detection of ovarian cancer.

Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE.

J Clin Oncol. 2010 May 1;28(13):2159-66. doi: 10.1200/JCO.2008.19.2484. Epub 2010 Apr 5.

29.

Targeting CCL11 in the treatment of ovarian cancer.

Nolen BM, Lokshin AE.

Expert Opin Ther Targets. 2010 Feb;14(2):157-67. doi: 10.1517/14728220903512983. Review.

PMID:
20055715
30.
31.

Screening for ovarian cancer: old tools, new lessons.

Nolen BM, Lokshin AE.

Cancer Biomark. 2010-2011;8(4-5):177-86. doi: 10.3233/CBM-2011-0210. Review.

PMID:
22045352
32.

The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease.

Bon JM, Leader JK, Weissfeld JL, Coxson HO, Zheng B, Branch RA, Kondragunta V, Lee JS, Zhang Y, Choi AM, Lokshin AE, Kaminski N, Gur D, Sciurba FC.

PLoS One. 2009 Aug 31;4(8):e6865. doi: 10.1371/journal.pone.0006865.

33.

Biological significance of prolactin in gynecologic cancers.

Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J, Mor G, Maxwell LG, Herberman RB, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE.

Cancer Res. 2009 Jun 15;69(12):5226-33. doi: 10.1158/0008-5472.CAN-08-4652. Epub 2009 Jun 2.

34.

Do serum biomarkers really measure breast cancer?

Jesneck JL, Mukherjee S, Yurkovetsky Z, Clyde M, Marks JR, Lokshin AE, Lo JY.

BMC Cancer. 2009 May 28;9:164. doi: 10.1186/1471-2407-9-164.

35.

Role of eotaxin-1 signaling in ovarian cancer.

Levina V, Nolen BM, Marrangoni AM, Cheng P, Marks JR, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE.

Clin Cancer Res. 2009 Apr 15;15(8):2647-56. doi: 10.1158/1078-0432.CCR-08-2024. Epub 2009 Apr 7.

36.

Surgical stress promotes tumor growth in ovarian carcinoma.

Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK.

Clin Cancer Res. 2009 Apr 15;15(8):2695-702. doi: 10.1158/1078-0432.CCR-08-2966. Epub 2009 Apr 7.

37.

Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.

Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK.

Gynecol Oncol. 2009 Apr;113(1):21-7. doi: 10.1016/j.ygyno.2008.12.003. Epub 2009 Jan 21.

38.

Autoantibodies for cancer detection: still cause for excitement?

Nolen BM, Lokshin AE.

Cancer Biomark. 2010;6(5-6):229-45. doi: 10.3233/CBM-2009-0137. Review.

PMID:
20938084
39.

Reproducibility of serum cytokines and growth factors.

Gu Y, Zeleniuch-Jacquotte A, Linkov F, Koenig KL, Liu M, Velikokhatnaya L, Shore RE, Marrangoni A, Toniolo P, Lokshin AE, Arslan AA.

Cytokine. 2009 Jan;45(1):44-9. doi: 10.1016/j.cyto.2008.10.014. Epub 2008 Dec 5.

40.

Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties.

Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE.

PLoS One. 2008 Aug 27;3(8):e3077. doi: 10.1371/journal.pone.0003077.

41.

Reproducibility of serum pituitary hormones in women.

Arslan AA, Gu Y, Zeleniuch-Jacquotte A, Koenig KL, Liu M, Velikokhatnaya L, Shore RE, Toniolo P, Linkov F, Lokshin AE.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1880-3. doi: 10.1158/1055-9965.EPI-08-0103.

42.

Use of novel autoantibody and cancer-related protein arrays for the detection of esophageal adenocarcinoma in serum.

Kilic A, Schuchert MJ, Luketich JD, Landreneau RJ, Lokshin AE, Bigbee WL, El-Hefnawy T.

J Thorac Cardiovasc Surg. 2008 Jul;136(1):199-204. doi: 10.1016/j.jtcvs.2008.01.012. Epub 2008 May 22.

43.

Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.

Nolen BM, Marks JR, Ta'san S, Rand A, Luong TM, Wang Y, Blackwell K, Lokshin AE.

Breast Cancer Res. 2008;10(3):R45. doi: 10.1186/bcr2096. Epub 2008 May 12.

44.

MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis.

Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Cisneros J, Macdonald SD, Pardo A, Sciurba F, Dauber J, Selman M, Gochuico BR, Kaminski N.

PLoS Med. 2008 Apr 29;5(4):e93. doi: 10.1371/journal.pmed.0050093.

45.

Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production.

Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE.

Exp Cell Res. 2008 Apr 15;314(7):1605-16. doi: 10.1016/j.yexcr.2007.12.027. Epub 2008 Jan 16.

46.

Reliability of tumor markers, chemokines, and metastasis-related molecules in serum.

Linkov F, Gu Y, Arslan AA, Liu M, Shore RE, Velikokhatnaya L, Koenig KL, Toniolo P, Marrangoni A, Yurkovetsky Z, Zeleniuch-Jacquotte A, Lokshin AE.

Eur Cytokine Netw. 2009 Mar;20(1):21-6. doi: 10.1684/ecn.2009.0146.

47.

Dynamic alteration of soluble serum biomarkers in healthy aging.

Shurin GV, Yurkovetsky ZR, Chatta GS, Tourkova IL, Shurin MR, Lokshin AE.

Cytokine. 2007 Aug;39(2):123-9. Epub 2007 Aug 8.

PMID:
17689975
48.

Early detection and staging of adenocarcinoma of the pancreas.

Pappas S, Federle MP, Lokshin AE, Zeh HJ 3rd.

Gastroenterol Clin North Am. 2007 Jun;36(2):413-29, x. Review.

PMID:
17533087
49.

Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.

Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE.

Clin Cancer Res. 2007 Apr 15;13(8):2422-8.

50.

Multianalyte profiling of serum cytokines for detection of pancreatic cancer.

Zeh HJ, Winikoff S, Landsittel DP, Gorelik E, Marrangoni AM, Velikokhatnaya L, Winans MT, Lee K, Moser A, Bartlett D, Lotze MT, Siegfried JM, Whitcomb D, Papacristou G, Slivka A, Bigbee WL, Lokshin AE.

Cancer Biomark. 2005;1(6):259-69. Erratum in: Cancer Biomark. 2006;2(3-4):175. Papacristou, G [added].

PMID:
17192050

Supplemental Content

Loading ...
Support Center